CD274 and triple-negative breast carcinoma: As representative of ICIs, the Food and Drug Administration has approved treatment with anti-PD-1 and anti-PD-L1 monoclonal antibodies for metastatic triple negative breast cancer (TNbreast cancer) immunotherapy.